Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to hold from buy, citing a less favourable earnings trajectory as the drugmaker...